Filter posts

The Return of the Biotech IPO

It isn’t just the volume of IPOs this summer that makes this window a victory …

BIO Investor Forum Veterans Moving Up with the Recent Biotech Deal Surge

As detailed in The New York Times, the potential for deal-making in the industry has …

BIO Convention Post-Con, Plus a Look Ahead

Last month, the biopharma community gathered for the industry’s largest event, the BIO International Convention. …

It Takes a Village: The New Pharma-VC Model for Biotech Investing

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in …

BayBio Op-ed featured in Xconomy

Gail Maderis, President & CEO of BayBio, recently discussed the strength of Northern California’s biotechnology …

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of …

BIO Investor Forum - Raring to Go: The Race to Treat Ultra-Rare Diseases

The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering …

Kinase Drug Development - Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last …

BIO Investor Forum: The New Kids on the Biotech Block

Where should biotech start-ups look for funding in the venture capital desert that is becoming …

Cancer Stem Cell Therapy: Real Or Just Hype?

Also known as tumor-initiating cells, cancer stem cells (CSC) have unique capability endemic to stem …